T he incidence of hemolysis after ventricular assist device implantation is low and has been estimated at Ϸ3%. 1 The Impella 2.5 (Abiomed; Danvers, MA) continuous-flow left ventricular assist device uses a microaxial pump that draws blood from the left ventricular cavity and expels it into the ascending aorta. The device is percutaneously inserted via the femoral artery and used as temporary circulatory support. In this case, we describe a patient who developed severe hemolytic anemia and acute kidney injury shortly after insertion of an Impella 2.5 ventricular assist device.
Case Reports
A 50-year-old male patient with idiopathic dilated cardiomyopathy and an ejection fraction of 15%, receiving home dobutamine infusion therapy, presented to the emergency department with multiple firings of his biventricular automatic implantable cardioverter defibrillator. The night before admission, the patient felt 2 shocks from his device. Interrogation of his automatic implantable cardioverter defibrillator revealed ventricular fibrillation before each firing. He began to receive continuous amiodarone infusion and was admitted to the coronary care unit. There were no episodes of hypotension recorded. He had jugular venous distention up to the angle of the mandible, a displaced point of maximum impulse to the left midaxillary line, and an audible S3 gallop. His extremities were warm to touch, with no clubbing, cyanosis, or edema.
Because he continued to have multiple ventricular fibrillation episodes, emergent ventricular fibrillation ablation was performed. His cardiac output by Fick was 3.4 L/min (Table) . Because the patient had an extremely low cardiac reserve, this was considered a high-risk procedure and the decision was made to use temporary circulatory support periprocedurally. Ventricular fibrillation recurred during ablation; given his low cardiac output, an Impella 2.5 left ventricular assist device was inserted and set on performance level 8, which offered 3.8 L/min of cardiac output (Table and Figure 1 ). During the procedure, he developed hematuria; 2 hours later, the patient became anuric and anemic.
A urinalysis showed dark brown urine positive for blood, with only 4 red blood cells per high-power field, but no casts. His hemoglobin and hematocrit decreased from 13.6 g/dL and 42% on admission to 8.9 g/dL and 22% in 24 hours ( Figure  2 ). Abdominal ultrasonography did not reveal any collections or hydronephrosis. Multiple serial laboratory panels drawn reported 4ϩ hemolysis. His creatinine increased from a baseline 0.7 mg/dL to 3.7 mg/dL (estimated glomerular filtration rate, 17 mL/min per 1.73 m 2 ) ( Figure 2 ). His lactate dehydrogenase level was Ͼ12 900 U/L, and his haptoglobin level was low. The result of hemoglobin electrophoresis was normal. A peripheral smear showed schistocytes (Figure 3) , and his plasma-free hemoglobin was 60 mg/dL. Multiple chest radiographs and a transthoracic ECG showed correct placement of the cannula. Echocardiography showed the inflow within the left ventricle and the outflow above the aortic valve. No position or flow alarms were activated after device placement. To reduce the level of hemolysis, the performance was changed to level 4. The Impella 2.5 ventricular assist device was subsequently removed 24 hours after insertion. The patient was transfused 2 U of packed red blood cells and received hemodialysis. Hemolysis resolved after device removal. His renal function did not recover ( Figure 2 ), and he continued receiving intermittent dialysis.
Discussion
Given his minimal cardiac reserve, it was considered that the patient would benefit from temporary use of a left ventricular assist device, such as the Impella 2.5, while undergoing ablation instead of an intra-aortic balloon pump and achieve more cardiac output. Several trials have shown superiority of the Impella 2.5 assist device over intra-aortic balloon pump in improving hemodynamic parameters, such as cardiac output, cardiac index, and mean arterial pressure, 2,3 but have not shown increased survival. 4 In 1 study, 3 hemolysis was sig- 
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nificantly higher in the first 24 hours and more packed red blood cells were transfused in the Impella 2.5 group but there was no difference in the serum creatinine level. Patients with hemolytic anemia after Impella 2.5 device insertion should be monitored for renal failure, and perhaps the institutional procedure should include serial ECGs, complete blood cell count, and free hemoglobin, lactate dehydrogenase, and haptoglobin measurements. Higher performance levels should be used for the shortest time periods, given the potential for more severe hemolysis. 4 The use of the Impella 2.5 should be considered only if absolutely necessary, and the length of time on this support should be minimized.
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